Zobrazeno 1 - 10
of 30
pro vyhledávání: '"Christine Guelcher"'
Autor:
Tewarit Sarachana, Neetu Dahiya, Vijaya L Simhadri, Gouri Shankar Pandey, Surbhi Saini, Christine Guelcher, Michael F Guerrera, Chava Kimchi-Sarfaty, Zuben E Sauna, Chintamani D Atreya
Publikováno v:
PLoS ONE, Vol 10, Iss 7, p e0132433 (2015)
Hemophilia A (HA) is a bleeding disorder caused by deficiency of functional plasma clotting factor VIII (FVIII). Genetic mutations in the gene encoding FVIII (F8) have been extensively studied. Over a thousand different mutations have been reported i
Externí odkaz:
https://doaj.org/article/503b9832d77043658b43b0c844141a69
Publikováno v:
The Journal of Haemophilia Practice. 8:86-97
The management of patients with haemophilia is complex and requires lifelong care to be delivered by a specialist multidisciplinary team. Haemophilia B results from a deficiency or absence in coagulation factor IX (FIX), leading to easy bruising, and
Publikováno v:
Haemophilia. 27:82-86
Over the last several decades, the increasing focus on women with inherited bleeding disorders (WBD) has brought more patients into Haemophilia Treatment Centres (HTC) around the world. These women present with unique challenges including a significa
Autor:
Lance Ballester, Christine Guelcher, Isabella McCary, Jan G. Kuhn, Gita Massey, Michael F. Guerrera, Leslie Raffini, Regina Butler
Publikováno v:
Haemophilia. 26:631-636
INTRODUCTION Emicizumab is a recombinant humanized bispecific antibody that bridges factor IXa and factor X to mimic the cofactor function of factor VIII. It is approved to prevent bleeding in patients with haemophilia A (HA). Outside of clinical tri
Autor:
Dawn Rotellini, Susan Hunter, Susan Cutter, Christine Guelcher, Spencer Dunn, David L. Cooper
Publikováno v:
Patient Related Outcome Measures. 10:257-266
Background The B-HERO-S study evaluated the impact of mild to severe hemophilia B on the lives of affected adults and children. Here, we assessed the impact of hemophilia B on relationships. Methods US adults with hemophilia B and caregivers of affec
Autor:
Leslie Raffini, Benjamin J. Samelson-Jones, Michael F. Guerrera, Jan G. Kuhn, Gita Massey, Regina Butler, Christine Guelcher
Publikováno v:
Haemophilia : the official journal of the World Federation of HemophiliaREFERENCES. 27(4)
Introduction Emicizumab is the first approved non-factor therapy for haemophilia A. It provides superior prophylactic bleeding control compared to other products in both patients with and patients without inhibitors. However, there is no real-world d
Autor:
Craig M. Kessler, Tyler W. Buckner, David L. Cooper, Michelle Witkop, Robert F. Sidonio, Wendy E. Owens, Christine Guelcher, Neeraj N. Iyer, Moshe Fridman, David B. Clark
Publikováno v:
European Journal of Haematology. 101:781-790
Objective To assess the reliability and validity of six patient-reported outcomes (PRO) instruments for evaluating health-related quality of life in adults with mild-severe hemophilia B and caregivers of children with hemophilia B, including affected
Autor:
Michael Recht, Wendy E. Owens, Neeraj N. Iyer, Skye Peltier, Mary Jane Frey, Tyler W. Buckner, Susan Hunter, Michelle Rice, Natalia Holot, David L. Cooper, Michelle Witkop, Christopher E. Walsh, Christine Guelcher, David B. Clark, Robert F. Sidonio, Neil Frick, Craig M. Kessler
Publikováno v:
European Journal of Haematology. 98:5-17
The Bridging Hemophilia B Experiences, Results and Opportunities Into Solutions (B-HERO-S) initiative was launched in an effort to address specific gaps in the understanding of the psychosocial impact of mild-moderate-severe hemophilia B. The origina
Publikováno v:
The Journal of Haemophilia Practice. 4:14-21
Introduction: As the focus on personalised treatment is refined, more products are brought to market and the life expectancy of persons with haemophilia increases, there will be an expanded need of experienced and expert healthcare providers to ensur
Autor:
Christine Guelcher, Janna M. Journeycake, Cliff Takemoto, Ellis J. Neufeld, Margaret V. Ragni, Robert F. Sidonio, Michael Recht, Dunlei Cheng, Jorge Caicedo, Michael D. Tarantino, Michael Denne, Susan Lattimore
Publikováno v:
Blood. 136:17-18
Introduction: It is anticipated that many patients with hemophilia are likely to switch from one coagulation factor product to a newer agent within the next few years. New replacement factor formulations have been developed using several approaches t